Tech Company Financing Transactions
Pathos AI Funding Round
On 10/26/2026, Pathos AI raised $237 million in Series E funding from Bristol Myers Squibb and private investors.
Transaction Overview
Company Name
Announced On
10/26/2026
Transaction Type
Venture Equity
Amount
$237,000,000
Round
Series E
Investors
Bristol Myers Squibb (Lead Investor)
Proceeds Purpose
The company intends to use the funds to further scale its platform's capabilities and accelerate the clinical development of its AI-steered portfolio, including advancing JSKN016 toward registrational studies and driving the clinical advancement of pocenbrodib, AZD4241, and DO-2.
Company Information
Company Status
Private & Independent
Industry
Artificial Intelligence
Mailing Address
600 West Chicago Avenue 150
Chicago, IL 60654
USA
Chicago, IL 60654
USA
Phone
Undisclosed
Website
Email Address
Overview
Pathos is a clinical-stage biotechnology company focused on re-engineering drug development, leveraging the power of advanced AI technologies to bring precision medicines to market through partnerships with biopharmaceutical companies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Iker Huerga
Browse more venture capital transactions:
Prev: 10/26/2026: DigitalXForce venture capital transaction
Next: 10/26/2026: Nevis venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs